コンテンツへスキップ
Merck
  • bFGF Promotes the Migration of Human Dermal Fibroblasts under Diabetic Conditions through Reactive Oxygen Species Production via the PI3K/Akt-Rac1- JNK Pathways.

bFGF Promotes the Migration of Human Dermal Fibroblasts under Diabetic Conditions through Reactive Oxygen Species Production via the PI3K/Akt-Rac1- JNK Pathways.

International journal of biological sciences (2015-06-17)
Hongxue Shi, Yi Cheng, Jingjing Ye, Pingtao Cai, Jinjing Zhang, Rui Li, Ying Yang, Zhouguang Wang, Hongyu Zhang, Cai Lin, Xianghong Lu, Liping Jiang, Aiping Hu, Xinbo Zhu, Qiqiang Zeng, Xiaobing Fu, Xiaokun Li, Jian Xiao
要旨

Fibroblasts play a pivotal role in the process of cutaneous wound repair, whereas their migratory ability under diabetic conditions is markedly reduced. In this study, we investigated the effect of basic fibroblast growth factor (bFGF) on human dermal fibroblast migration in a high-glucose environment. bFGF significantly increased dermal fibroblast migration by increasing the percentage of fibroblasts with a high polarity index and reorganizing F-actin. A significant increase in intracellular reactive oxygen species (ROS) was observed in dermal fibroblasts under diabetic conditions following bFGF treatment. The blockage of bFGF-induced ROS production by either the ROS scavenger N-acetyl-L-cysteine (NAC) or the NADPH oxidase inhibitor diphenylene iodonium chloride (DPI) almost completely neutralized the increased migration rate of dermal fibroblasts promoted by bFGF. Akt, Rac1 and JNK were rapidly activated by bFGF in dermal fibroblasts, and bFGF-induced ROS production and promoted dermal fibroblast migration were significantly attenuated when suppressed respectively. In addition, bFGF-induced increase in ROS production was indispensable for the activation of focal adhesion kinase (FAK) and paxillin. Therefore, our data suggested that bFGF promotes the migration of human dermal fibroblasts under diabetic conditions through increased ROS production via the PI3K/Akt-Rac1-JNK pathways.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
トリス(tert-ブトキシ)シラノール, 99.999%
Sigma-Aldrich
MISSION® esiRNA, targeting human RAC1
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Rac1